TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32017677
Drug: Higher risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher risk for vaccine viremia (conception before or <14 days after vaccination)
Study: 32017677
Drug: Lower risk
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower risk for vaccine viremia (conception >15 days after vaccination)
Study: 32297653
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml ropivacaine 0.75%
Study: 33827915
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) beyond 6.5 hours
Study: 33827915
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) within 6.5 hours
Study: 32053101
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg generic sofosbuvir in fasted state
Study: 32053101
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg generic sofosbuvir in fasted state
Study: 32053101
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily for 8 days
Study: 32053101
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg generic sofosbuvir after a high-fat meal
Study: 32053101
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg generic sofosbuvir
Study: 34781421
Drug: Dexmedetomidine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (2.0 μg/kg, i.m.) in 2.5 mL saline
Study: 34781421
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo, i.m.) 2.5 mL
Study: 32969758
Drug: Reldesemtiv 150
Normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reldesemtiv 150 mg bid
Study: 32969758
Drug: Reldesemtiv 300
Normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reldesemtiv 300 mg bid
Study: 32969758
Drug: Reldesemtiv 450
Normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reldesemtiv 450 mg bid
Study: 34218726
Drug: All reldesemtiv
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All reldesemtiv doses combined
Study: 35988059
Drug: Eldecalcitol capsule
Normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Eldecalcitol capsule (0.75 μg) under fasting conditions
Study: 35988059
Drug: Eldecalcitol capsule
Normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Eldecalcitol capsule (0.75 μg) under fed conditions
Study: 35988059
Drug: Eldecalcitol capsule
Normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Eldecalcitol capsule (0.75 μg)
Study: 32538182
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of vitamin D (28 IU/kg)
Study: 32538182
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing of vitamin D (2000 IU/day)
Study: 32538182
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (weight-based and fixed dosing)
Study: 32538182
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of vitamin D
Study: 36235651
Drug: Dual supplementation
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual supplementation of multi-strain probiotic (B. lactis Bi‐07, L. paracasei Lpc‐37, L. acidophilus NCFM, B. lactis Bl‐04) and omega-3 supplements for eight weeks
Study: 36235651
Drug: Dual supplementation
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual supplementation of multi-strain probiotic and omega-3 supplements
Study: 33121627
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg Simmental bull seminal plasma protein per mL egg yolk‐citrate extender (T1)
Study: 33121627
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Simmental bull seminal plasma protein per mL egg yolk‐citrate extender (T2)
Study: 32633896
Drug: Transcutaneous application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous application of gaseous CO2 (20 therapies with medical-grade CO2 gas)
Study: 32633896
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same treatment with air)
Study: 33478324
Drug: 1% iodiconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% iodiconazole cream (0.4 g)
Study: 33478324
Drug: 2% iodiconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% iodiconazole cream (0.4 g)
Study: 33478324
Drug: 4% iodiconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% iodiconazole cream (0.4 g)
Study: 32505485
Drug: intermittent theta
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent theta burst protocols (iTBS) rTMS (50 Hz, 900 pulses, 20 daily sessions over 4 weeks)
Study: 35439754
Drug: OPF‐105 (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPF‐105 (novel all‐in‐one peripheral parenteral nutrition solution)
Study: 35439754
Drug: BFL (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFL (combination of a commercially available PPN solution and fat emulsion)
Study: 34628077
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention based on cognitive-behavioral therapy delivered by Medical Assistants in primary care.
Study: 32705831
Drug: Celecoxib capsules
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib capsules (200 mg once daily)
Study: 35268070
Drug: c‐NCS diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: c‐NCS diet (50‐100 mg/day NCS)
Study: 35268070
Drug: NCS‐f diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCS‐f diet (less than 10 mg/day NCS)
Study: 33065120
Drug: CSL112 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 6 g
Study: 32279349
Drug: Short-term patch
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term patch test protocol with an application period of 20 minutes
Study: 32279349
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test results
Study: 33350361
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Lactobacillus fermentum CECT5716 and Bifidobacterium breve CECT7263 (1×10^8 cfu/day per strain)
Study: 33350361
Drug: Simethicone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone (80 mg/day)
Study: 36267269
Drug: Dexmedetomidine postconditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine postconditioning (DPOC) via intravenous administration at 0.6 μg kg−1 for 10 min immediately after unclamping the renal artery
Study: 36267269
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received saline administered under the same protocol as DPOC
Study: 35467064
Drug: AMX‐CLG (1875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMX‐CLG (1875/125 mg of AMX‐CL orally 1–2 h prior to surgery)
Study: 35467064
Drug: AMXG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMXG (2 g of amoxicillin orally)
Study: 33087119
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg every 4 weeks (Q4W)
Study: 33469316
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg Q4W
Study: 32705817
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with vigabatrin (80–150 mg/kg/day)
Study: 32705817
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of epileptic seizures
Study: 34799110
Drug: Altered crude
Normalized name: COAL TAR,CRUDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altered crude protein (CP) content in dietary supplements (15.3% during baseline, 19.3% during experimental)
Study: 34799110
Drug: Regular supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular supplements (13.5% during baseline, 14.8% during experimental)
Study: 33973327
Drug: RNase1 pretreatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RNase1 pretreatment 24 hours before A. hydrophila injection
Study: 34311528
Drug: EPP-AF® 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPP-AF® 400 mg/day
Study: 34311528
Drug: EPP-AF® 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPP-AF® 800 mg/day
Study: 35654363
Drug: Ranibizumab (0.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5-mg or 2.0-mg) administered monthly or pro re nata over 24 months
Study: 32926835
Drug: Single-dose pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose pneumococcal conjugate vaccine
Study: 32926835
Drug: Two-dose primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine
Study: 35034025
Drug: L-FABP biomarker
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-FABP biomarker assay
Study: 35034025
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-FABP)
Study: 33038728
Drug: No bio-fertilizers
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bio-fertilizers (NF) with 200 mg kg−1 SDZ
Study: 33038728
Drug: Co-application of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-application of bio-fertilizers and SDZ (100 and 200 mg kg−1)
Study: 33038728
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg kg−1 SDZ with no bio-fertilizers
Study: 37453737
Drug: Abatacept monotherapy
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept monotherapy
Study: 35248272
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both MT interventions
Study: 34105177
Drug: Casimersen (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casimersen (4, 10, 20, and 30 mg/kg weekly infusions)
Study: 35193046
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure (SAA)
Study: 35219449
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine (0.3 mg kg−1)
Study: 35505644
Drug: Tramadol via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol via patient-controlled analgesia (PCA) pump (600 mg daily)
Study: 35505644
Drug: Intermittent tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent tramadol administration
Study: 33570975
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation and treatment-as-usual (TAU)
Study: 32186656
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg IV on days 0 and 14, 500 mg at months 12 and 18) combined with short-term prednisone regimen
Study: 32186656
Drug: PDAI score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDAI score of 45 or higher and/or persistent anti-DSG1 or anti-DSG3 antibody values at month 3
Study: 32878514
Drug: M2000 (mannuronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2000 (mannuronic acid) 1000 mg/day (two 500 mg capsules daily)
Study: 32878514
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug (interferon beta‐1a, interferon beta‐1b)
Study: 33357709
Drug: HFD +
Normalized name: Hydrofluorodiethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFD + OCN (3 μg/bird, 1 time/2 d, i.m.)
Study: 34525277
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (30-µg doses, two doses at 21 days apart)
Study: 36331844
Drug: Non-cultured epidermal
Normalized name: omidubicel
DrugBank: Omidubicel (DB17132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cultured epidermal cell suspension
Study: 36941575
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care chemotherapy
Study: 32507144
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment associated with exercises (OMT/EG)
Study: 37086227
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg orally twice daily for 7 days starting immediately post-procedure (group B)
Study: 37086227
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg orally twice daily for 7 days (group B)
Study: 37074705
Drug: Tralokinumab 150
Normalized name: Tralokinumab 150 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 150 mg
Study: 34798037
Drug: Etrolizumab 105
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab 105 mg subcutaneously once every 4 weeks
Study: 34798038
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg intravenously at 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
Study: 33899093
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (targeted therapy)
Study: 33683586
Drug: Substrate with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substrate with organic compost (S1) at 50% effluent dose
Study: 33683586
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment at doses 25% and 50% in S1
Study: 32283762
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (180 mg/day for 12 weeks)
Study: 32548299
Drug: Tumor Sphericity
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Sphericity (SPH) at early-treatment (T1)
Study: 36735054
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg (Prolia, Amgen Inc.) administered at baseline, 6, and 12 months
Study: 39131711
Drug: Risankizumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (various doses)
Study: 35096113
Drug: Ginger (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (500 mg twice a day)
Study: 32799397
Drug: Other consumer
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other consumer medication information (CMI) with SMART program
Study: 32495663
Drug: Multiple-dose GnRH-a
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose GnRH-a
Study: 32495663
Drug: Single-dose GnRH-a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose GnRH-a
Study: 32746864
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine with 20 μg of fentanyl (1 ml)
Study: 32746864
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine with 5 μg of DEX (1 ml)
Study: 32746864
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine with saline (1 ml)
Study: 34067240
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with Harpagophytum procumbens, Zingiber officinale and Bixa orellana (2 g/day in 6 doses for 4 weeks)
Study: 35790450
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry (MTC) capsules
Study: 36038585
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 50 mg × 3 daily
Study: 36038585
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate 50 mg × 3
Study: 36038585
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 150 mg × 1
Study: 36038585
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate 150 mg × 1
Study: 33037644
Drug: Education sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education sessions for interns, residents, and clinical pharmacists about appropriate analgesic prescribing.
Study: 35872697
Drug: Metformin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (control group)
Study: 33006602
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of diclofenac etalhyaluronate (DF-HA) intra-articularly at weeks 0, 4, and 8
Study: 36216432
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (triggered by Hb ≤100 g/L)
Study: 36216432
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (triggered by Hb ≤70 g/L)
Study: 33962104
Drug: Target genes
Normalized name: Genesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target genes involved in biological pathways
Study: 33484775
Drug: Elafibranor 80
Normalized name: elafibranor 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elafibranor 80 mg
Study: 33314326
Drug: RP3128 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP3128 (25, 50, 100, 200, and 400 mg single doses; 25, 100, and 400 mg once daily for 7 days)
Study: 34394889
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin pill (given on the basis of conventional treatment)
Study: 33172321
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy (hot pack therapy, interferential current, myofascial relaxation, cervical dynamic isometric exercises)
Study: 34557087
Drug: Metamizole 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizole 1,000 mg three times daily for 7 days
Study: 34557087
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for 7 days
Study: 32530733
Drug: Two-dose EV71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose EV71 vaccination
Study: 32129511
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of romiplostim (n = 621)
Study: 32129511
Drug: HCP administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCP administration of romiplostim (n = 133)
Study: 32129511
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of romiplostim
Study: 32129511
Drug: HCP administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCP administration of romiplostim
Study: 35777773
Drug: F ENO-based
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F ENO-based asthma management (adjustment of asthma treatment according to exhaled nitric oxide and symptoms every 6-12 weeks)
Study: 35777773
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no treatment adjustment as part of the trial)
Study: 32444994
Drug: BAX602 spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAX602 spray
Study: 34693688
Drug: Cellex (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellex (1 ml subcutaneously once daily for 10 days)
Study: 32663909
Drug: Decoglurant 5
Normalized name: Decoglurant
DrugBank: Decoglurant (DB11923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoglurant 5 mg
Study: 32663909
Drug: Decoglurant 15
Normalized name: Decoglurant
DrugBank: Decoglurant (DB11923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoglurant 15 mg
Study: 32663909
Drug: Decoglurant 30
Normalized name: Decoglurant
DrugBank: Decoglurant (DB11923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoglurant 30 mg
Study: 34840669
Drug: Melatonin 0.5
Normalized name: melatonin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.5 mg/kg once a day, in the morning (MEL group)
Study: 34817419
Drug: Low-dose control
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose control
Study: 32144955
Drug: Zanubrutinib 480
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 480 mg
Study: 32144955
Drug: Zanubrutinib 160
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg
Study: 34362445
Drug: 12-month external
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month external implementation intervention including developmental evaluation, on-site visit, and monthly facilitation calls.
Study: 33338583
Drug: Ashwagandha 300
Normalized name: Jarrow Formulas Ashwagandha 300 mg Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha 300 mg, twice daily, orally for 8 weeks